00:00It's Benzinga bringing Wall Street to Main Street.
00:02Eli Lilly is in advanced talks to acquire Colonia Therapeutics for more than $2 billion,
00:09according to CNBC. A deal could be reached as soon as Monday and may include additional
00:14milestone-based payments. Reuters could not verify the report and neither company responded
00:19to requests for comment. Colonia is a clinical stage biotech company developing genetic medicines
00:25with a focus on CAR T-cell therapies that modify immune cells to target and destroy cancer.
00:31The acquisition would expand Lilly's cancer portfolio, which includes J. Pirka and Verzinio.
00:37The company has been expanding into multiple therapeutic areas through acquisitions,
00:41including a February deal to acquire Orna Therapeutics for up to $2.4 billion in cash.
00:47For all things money, visit Benzinga.com.
Comments